Search Results

DQA, a patient specific quality assurance in tomotherapy, is usually performed using an ion chamber and a film. The result of DQA is analysed with the treatment planning system called Tomo Planning Station (TomoPS). The two-dimensional dose distribution of film measurement is compared with the dose distribution calculated by TomoPS using the gamma-index analysis. In gamma-index analysis, the criteria such as 3%/3 mm is used and we verify that whether the rate of number of points which pass the criteria (pass rate) is within tolerance. TomoPS does not provide any quantitative information regarding the pass rate. In this work, a method to get the pass rate of the gamma-index analysis was suggested and a software PassRT which calculates the pass rate was developed. The results of patient specific QA of the intensity modulated radiation therapy measured with I'mRT MatriXX (IBA Dosimetry, Germany) and DQA of tomotherapy measured with film were used to verify the proposed method. The pass rate was calculated using PassRT and compared with the pass rate calculated by OmniPro I'mRT (IBA Dosimetry, Germany). The average difference between the two pass rates was 0.00% for the MatriXX measurement. The standard deviation and the maximum difference were 0.02% and 0.02%, respectively. For the film measurement, average difference, standard deviation and maximum difference were 0.00%, 0.02% and 0.02%, respectively. For regions of interest smaller than 24.3x16.6 cm2 the proposed method can be used to calculate the pass rate of the gamma index analysis to one decimal place and will be helpful for the more accurate DQA in tomotherapy.
Humans ; Hypogonadism ; Mitochondrial Diseases ; Ophthalmoplegia

1.Diagnostic Evaluation of Hypogonadism.

2.Gonadotropin-releasing hormone(GnRH) therapy in male patients with hypothalamic hypogonadism.

3.A Manual of 2008 ISA, ISSAM, EAU, EAA and ASA Recommendations: Investigation, Treatment and Monitoring of Late-onset Hypogonadism in Males.

4.Response to comment on “Hypogonadotrophic hypogonadism due to a mutation in the luteinizing hormone β-subunit gene”.

5.Comment on “Hypogonadotrophic hypogonadism due to a mutation in the luteinizing hormone β-subunit gene”.

6.Hormone Therapy of Male Hypogonadism.

7.Hypogonadotrophic hypogonadism due to a mutation in the luteinizing hormone β-subunit gene.

8.Bone mineral density in premenopausal amenorrheic women with hypogonadism.

9.Correlation between growth hormone reserve and ovarian response to human menopausal gonadotropin in patient with hypogonadotropic hypogonadism.

10.A Method to Calculate a Pass Rate of the gamma-index Analysis in Tomotherapy Delivery Quality Assurance (DQA).

Display Mode

Output Records

File Type